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Review article 
 
Evaluation and management of inherited disorders of surfactant 
metabolism  
 
Aaron Hamvas 
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Objective  To review the pathophysiology, evaluation, management, and outcomes of children with inherited disorders 
of surfactant metabolism due to mutations in the genes encoding surfactant proteins-B or -C (SFTPB, SFTPC), ATP 
binding cassette member A3 (ABCA3), and thyroid transcription factor (NKX2.1).   
Data sources  Review of the literature, previous work from the author’s and collaborators’ laboratories, St. Louis 
Children’s Hospital Lung Transplant Database.   
Study selection  Key articles in the field, author’s work. 
Results  Inherited disorders of surfactant metabolism present as acute, severe respiratory dysfunction in the neonatal 
period (SFTPB, ABCA3, NKX2.1) or as chronic respiratory insufficiency in later infancy and childhood which is of variable 
onset, severity, and course (SFTPC, ABCA3, NKX2.1). Diagnosis is established with sequencing the relevant genes; lung 
biopsy with electron microscopy is a useful adjunct.  For surfactant protein-B and ABCA3 deficiency presenting with 
acute neonatal disease, treatment options are limited to lung transplantation or compassionate care. For the more 
chronic presentations of surfactant protein-C, ABCA3, and NKX2.1 associated disease, the natural history is variable and 
therefore individualized, supportive care is appropriate,  
Conclusions  Inherited disorders of surfactant metabolism are rare, but informative diseases that provide unique 
opportunities for understanding mechanisms of respiratory disease in newborns and children.  
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he pulmonary surfactant is a unique phospholipid and 
protein complex that is synthesized, packaged, and 
secreted by alveolar type II cells.1-3 The phospholipid 
components constitute approximately 90% by weight of 
pulmonary surfactant, of which 70%–80% is 
phosphatidylcholine (PC). The protein components 
constitute approximately 10% by weight of pulmonary 
surfactant, half of which consists of four 
surfactant-associated proteins, surfactant proteins A, B, C, 
and D (SP-A, SP-B, SP-C, and SP-D). Pulmonary 
surfactant is unique in its abundance of dipalmitoylated 
PC (DPPC), which, along with SP-B and SP-C, lowers 
surface tension and prevents atelectasis at end-expiration. 
SP-A and SP-D participate in host defense in the lung. A 
regulated cycle of synthesis, secretion, and recycling 
involves both the phospholipid and protein components 
of pulmonary surfactant; SP-A and granulocyte- 
macrophage colony stimulating factor (GM-CSF) 
contribute to surfactant recycling and catabolism.  The 
ATP binding cassette member A3 (ABCA3) is a 
transporter protein that is thought to transport 
phospholipid into lamellar bodies, the organelles within 
the alveolar type II cell in which the final processing and 
assembly of the surfactant components occurs prior to 
secretion. Thyroid transcription factor 1, encoded by the 
NKX2.1 gene, regulates expression of many genes 
essential for lung development and function, including 
those encoding SP-B and SP-C (SFTPB and SFTPC, 
respectively).   
INHERITED DISORDERS OF PULMONARY 
SURFACTANT METABOLISM 
 
An overview of the known disorders of pulmonary 
surfactant metabolism associated with mutations in the 
surfactant proteins-B and C, ABCA3, and thyroid 
transcription factor genes is provided in Table 1.  To 
date, no inherited deficiencies of SP-A or SP-D have been 
identified in the newborn period, although mutations in 
the gene encoding SP-A (SFTPA2) have been associated 
with idiopathic pulmonary fibrosis in adults.4   
 
Two types of clinical presentation bring infants and 
children with inherited disorders of surfactant metabolism 
to attention. In the first and most dramatic, term 
newborns develop severe respiratory failure shortly after 
birth that requires significant ventilatory support, is 
minimally or transiently responsive to surfactant 
replacement, may require extracorporeal membrane 
oxygenation (ECMO), and fails to improve after the first 
week of life. Secondary pulmonary hypertension may 
accompany the clinical syndrome and may be partially 
responsive to inhaled nitric oxide. On chest X-rays,  
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Table 1. Characteristics of surfactant disorders 
ABCA3 deficiency Items SP-B deficiency 
Acute Chronic 
SP-C associated disorders NKX2.1 
Presentation Acute, neonatal period Neonatal period Interstitial lung disease in 
infancy and childhood
Interstitial lung disease 
infancy and childhood 
Acute neonatal RDS and older presentation 
of chronic lung disease 
Frequency 1 per million Unknown Unknown Unknown 
Natural history Lethal in newborn period Lethal Variable Variable Variable, associated with hypothyroidism 
and chorea 
Inheritance Recessive Recessive Dominant 
Sporadic and inherited 
Dominant 
Sporadic and inherited 
Diagnosis Genetic analysis Genetic analysis Genetic analysis Genetic analysis 
 
diffuse haziness and air bronchograms mimic the 
appearance of RDS in premature infants. This acute 
presentation is typical for infants with loss of function 
mutations in SFTPB or ABCA3, but has also been seen in 
a small number of infants with mutations in SFTPC and 
NKX2.1, as well.5-8  
 
A more chronic clinical presentation and variable course 
of disease has been seen in children with mutations in 
SFTPC, ABCA3 and NKX2.1.8-11 Some children may 
present in the newborn period with milder respiratory 
dysfunction that is ascribed to transient tachypnea of the 
newborn or congenital pneumonia while those presenting 
beyond the newborn period develop gradual onset of 
respiratory insufficiency, hypoxemia, failure to thrive and 
interstitial lung disease on chest radiographs. While some 
cases have had a history of an associated viral illness or 
chronic aspiration, these features have not consistently 
been elicited, suggesting that other genetic or 
environmental modifiers influence the presentation of 
disease. This variability in severity and course of the 
disease is not mutation specific and thus precludes 
accurate assessment of prognosis for an individual. 
 
Although many premature infants have been evaluated, 
SP-B deficiency has not been identified in infants <30 
weeks gestation, though no systematic analysis of the 
prevalence of disease in premature infants has been 
performed. In contrast, ABCA3 mutations have been 
identified in premature infants whose respiratory 
dysfunction is more severe than would be anticipated for 
gestational age, which raises the question as to whether 
mutations in ABCA3 may provide a genetic susceptibility 
for the risk and severity of RDS in newborns.12  
 
SP-B deficiency   
This autosomal recessive disorder is rare, with a disease 
frequency of approximately 1 per million live births in 
the United States. Over 30 mutations in SFTPB have been 
identified that result in partial to complete absence of 
SP-B protein. The most common mutation, a GAA 
substitution for C in codon 121, the “121ins2” mutation, 
is associated with approximately 70% of the cases of 
SP-B deficiency; the carrier frequency is approximately 1 
per 1000 individuals.13 Though SP-B deficiency has been 
recognized in diverse racial and ethnic groups, a common 
haplotype bearing the 121ins2 mutation suggests a 
founder effect among people of European descent.14 Most 
of the other identified mutations are family-specific and 
have all been inherited; no spontaneous mutations in 
SFTPB have been identified.  
 
The absence of SP-B, the presence of an incompletely 
processed proSP-C, and a generalized disruption of 
surfactant metabolism cause surfactant dysfunction and 
the clinical syndrome. The threshold of mature SP-B 
expression required for normal surfactant function in 
humans is unknown. Patients with partial SP-B deficiency 
and approximately 10% of normal SP-B expression have 
a clinical picture similar to that of infants while 
heterozygous parents with presumably 50% of normal 
SP-B expression have normal respiratory function. 
Murine models that conditionally express SP-B develop 
respiratory failure when SP-B expression is 
approximately 25% of normal values.15,16 Thus, there 
appears to be a limited margin of SP-B expression that 
permits normal surfactant function, and any 
environmental or developmental condition that disrupts 
SP-B expression may result in significant respiratory 
dysfunction in genetically susceptible individuals.   
 
ABCA3 deficiency 
ABCA3 is most highly expressed in lung tissue, more 
specifically, on the limiting membrane of lamellar bodies 
in alveolar Type II cells, but is also expressed in the heart, 
brain, pancreas, kidney, and platelets.17-19 The frequency 
of disease due to recessive mutations in ABCA3 in the 
population is unknown although preliminary studies 
suggest that ABCA3 deficiency may be the most common 
of these disorders of surfactant homeostasis. Over 180 
mutations in ABCA3 have been identified in association 
with lethal RDS in newborns and with chronic respiratory 
insufficiency in children. One variant, a substitution of 
valine for glutamic acid in codon 292 (E292V) has been 
found in approximately 0.4% of the general population 
and in 4% of a cohort of infants with RDS, suggesting 
that this variant contributes to the risk or severity of 
respiratory disease in susceptible individuals.12  
  
While the exact role of ABCA3 in surfactant metabolism 
remains unknown, data from humans and mice suggest 
that ABCA3 mediates PC and phosphatidylglycerol 
transport into lamellar bodies. This disrupted 
phospholipid transport leads to reduced surfactant 
function.5,20-22 The function of ABCA3 in other tissues 
remains unknown.  
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Surfactant protein-C disorders  
SP-C is a lung specific peptide that functions to lower 
surface tension. The frequency of disease due to 
mutations in SFTPC in the population is unknown. Over 
35 dominant mutations in SFTPC have been identified in 
association with familial and sporadic acute and chronic 
lung disease in patients ranging in age from newborn to 
adult. The most common mutation is a threonine 
substitution for isoleucine in codon 73 (I73T) and is 
associated with 25% of the cases of both sporadic and 
inherited SP-C associated disease, but we failed to find it 
in a population-based screen of over 4000 individuals.10,12 
A high degree of recombination within SFTPC may 
contribute to the high rate of spontaneous disease-causing 
mutations.23  
  
Mutations in SFTPC result in production of misfolded 
proSP-C that accumulates within cellular secretory 
pathways (endoplasmic reticulum and Golgi) in the 
alveolar type II cell resulting in activation of cell stress 
responses and apoptosis.24,25 It is unclear if the presence 
of proSP-C or the absence of mature SP-C impairs 
surfactant function, and furthermore, if this altered 
surfactant function contributes to the pathogenesis of 
symptomatic disease.  
 
Disease associated with mutations in NKX2.1  
Thyroid transcription factor is expressed in the brain, 
thyroid gland, and lung and is critical for the development 
of these organs. Dominantly expressed mutations in 
NKX2.1 result in a constellation of hypothyroidism, 
choreoathetosis and respiratory disease: the 
“brain-thyroid-lung syndrome”.8,26,27 The respiratory 
disease, if present, may manifest as RDS in the newborn 
period or as recurrent pulmonary infections or interstitial 
lung disease in later childhood. The frequency of disease 
and mutations is unknown. Over 20 mutations have been 
reported in the literature, but no common mutations have 
been identified. Similar to mutations in SFTPC, 
approximately half arise spontaneously.   
 
Other lung diseases associated with surfactant-related 
genes    
Mutations in the gene encoding the α-subunit of the 
granulocyte-macrophage colony stimulating factor 
receptor (CSF2RA) have been associated with pulmonary 
alveolar proteinosis in children and mutations in the 
surfactant protein A gene (SFTPA2) have been associated 
with idiopathic pulmonary fibrosis and lung cancer in 
adulthood.4,28   
 
DIAGNOSIS OF INHERITED DISORDERS OF 
SURFACTANT METABOLISM 
 
Genetic analysis  
Establishing a diagnosis of an inherited disorder of 
surfactant metabolism should occur promptly so that 
deliberate discussions of therapeutic options can proceed, 
especially in the cases of acute neonatal presentation. 
Sequence analysis of the relevant genes, SFTPB and 
ABCA3 for acute neonatal presentation and SFTPC and 
ABCA3 for later onset presentation, provides the most 
direct means to establish a diagnosis, and is available in 
clinical and research laboratories. Associated 
hypothyroidism should prompt sequence analysis of 
NKX2.1. The relatively small sizes of SFTPB and SFTPC 
permit rapid results that can be incorporated into clinical 
discussions and decisions, whereas the significantly 
larger size of ABCA3 makes the analysis more time 
consuming and more difficult to incorporate into clinical 
decisions in the face of a critically ill, rapidly 
deteriorating child. Further complicating genetic analysis 
is the fact that in all these genes, most mutations are 
family specific and distinguishing true disease causing 
mutations from rare yet benign sequence variants can be 
difficult. 
 
Tissue analysis  
Despite the severity of illness in many of these children, 
histopathologic evaluation of lung tissue can be a 
valuable adjunct to genetic diagnosis. At the time of lung 
biopsy, close coordination among the neonatologist or 
pulmonologist, surgeon, and pathologist is necessary to 
ensure that the tissue is prepared immediately and 
appropriately for electron microscopy, histopathology, 
and future molecular or proteomic analysis. A suggested 
tissue procurement procedure is outlined by Langston et 
al.29 Sentinel findings of a surfactant metabolic disorder 
include diffuse alveolar type II cell hyperplasia, alveolar 
septal thickening and alveolar proteinosis. Examination 
of the lamellar body morphology with electron 
microscopy can also provide insight: disorganized 
lamellar bodies suggest SP-B deficiency while dense 
lamellar bodies or those with eccentric dense inclusions 
suggest ABCA3 deficiency.7,30,31    
 
LUNG TRANSPLANTATION FOR INHERITED 
DISORDERS OF SURFACTANT METABOLISM 
  
No mechanism-specific interventions are available for 
any of surfactant disorders, and thus lung transplantation 
provides an option to prolong survival. The determination 
for lung transplantation is based on combinations of 
interacting factors that include the specific molecular 
defect, the degree of illness and trajectory of the clinical 
course, the absence of extrapulmonary organ dysfunction, 
the need for and ability to transport to a pediatric lung 
transplant center, and, most importantly, the desire of the 
family to begin such an undertaking. Therefore, 
considerable effort goes into helping families understand 
the implications of a decision to pursue lung 
transplantation, especially the fact that transplantation 
substitutes a series of chronic problems for what 
otherwise is an imminently lethal problem.  
 
The five year survival for infants who have undergone 
transplantation is approximately 50%, with short term 
mortality due predominantly to infection and long term 
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mortality due to bronchiolitis obliterans or infection 
(Table 2). In addition to bronchiolitis obliterans, long 
term mortality results from lymphoproliferative 
malignancy. The post-transplant outcomes of the inherited 
surfactant deficiency syndromes are similar, suggesting 
that these outcomes reflect consequences of 
transplantation rather than the underlying disease.32,33  
   
Table 2. Post-transplant morbidity and mortality for infants with 
surfactant disorders 
Items 
SP-B 
deficiency 
SP-C 
disorders 
ABCA3 
deficiency
Total
Post-transplant complications (%) 
Acute rejection 
PTLD 
Bronchiolitis obliterans 
 
12 
12 
25 
 
40 
20 
60 
 
58 
17 
42 
 
40
16
40
Causes of death (n) 
Bronchiolitis obliterans infection  
Gastroenteritis                  
Malignancy 
 
1 
3 
1 
– 
 
1 
– 
– 
1 
 
4 
1 
– 
– 
 
6
4
1
1
PTLD: Post-transplant lymphoproliferative disorder. 
 
While the survival rate is a critical factor, the quality of 
that survival plays a larger role in some families’ 
decision-making. The degree and duration of illness in the 
pre-transplantation period contribute to the risk of 
adverse neurodevelopmental outcomes, especially in 
infants. Nearly all of the ventilated infants have had 
oral-motor feeding difficulties that require long-term (1–2 
years) nasogastric or gastrostomy feedings and most 
infants have gross motor delays that improve in the first 2 
years. Patients also must adhere to an extensive 
immunosuppression regimen, regular monitoring of blood 
levels of immunosuppressive drugs, physical, 
occupational, and speech therapy, and feeding 
interventions. These significant short and long-term 
challenges have prompted approximately half the families 
of affected children to decline transplantation and choose 
compassionate care for their infants.   
  
In summary, these lung-specific disorders of surfactant 
metabolism are ideal candidate diseases for which lung 
transplantation can reconstitute the function of the mutant 
gene and also provide a unique opportunity to understand 
surfactant biology. The complexities and heterogeneous 
outcomes of transplantation, though, necessitate 
deliberate and informed decision-making before 
proceeding. Understanding the mechanisms underlying 
respiratory dysfunction in these disorders holds the hope 
that mechanism-specific interventions can be developed 
in the future.    
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